白血病是一种危险的恶性肿瘤，每年在世界范围内造成数千人死亡。尽管针对受影响个体的治疗策略取得了许多进展，但患病率和死亡率仍然很高。目前，在临床肿瘤学中使用的大多数抗肿瘤药物都利用凋亡信号通路诱导肿瘤细胞死亡。累积的数据已经显示，诱导肿瘤细胞凋亡与更高的肿瘤消退和生存率之间存在直接关联。至今，褪黑激素作为一种强效抗肿瘤剂的功效已经得到确立。多个肿瘤（如子宫内膜癌、造血系统肿瘤和乳腺癌）中已有报告显示褪黑激素浓度的变化。研究结果表明，褪黑激素的抗癌特性，如其促氧化功能和促进凋亡的能力，提示了将这种天然物质作为创新癌症治疗方法中的有希望的制剂的可能性。褪黑激素通过调节许多凋亡促进因子（包括线粒体、细胞色素c、Bcl-2、活性氧产生和凋亡受体）来刺激细胞凋亡。本文旨在通过凋亡途径进一步评估褪黑激素的抗癌效果，考虑到细胞凋亡在癌症发病机制中的作用。褪黑激素的作用可能意味着它适合与放疗和化疗等其他治疗方法一起作为辅助剂使用。版权所有 © 2023 Mafi、Rismanchi、Gholinezhad、Mohammadi、Mousavi、Hosseini、Milasi、Reiter、Ghezelbash、Rezaee、Sheida、Zarepour、Asemi、Mansournia 和 Mirzaei.

Leukaemia is a dangerous malignancy that causes thousands of deaths every year throughout the world. The rate of morbidity and mortality is significant despite many advancements in therapy strategies for affected individuals. Most antitumour medications used now in clinical oncology use apoptotic signalling pathways to induce cancer cell death. Accumulated data have shown a direct correlation between inducing apoptosis in cancer cells with higher tumour regression and survival. Until now, the efficacy of melatonin as a powerful antitumour agent has been firmly established. A change in melatonin concentrations has been reported in multiple tumours such as endometrial, hematopoietic, and breast cancers. Findings show that melatonin's anticancer properties, such as its prooxidation function and ability to promote apoptosis, indicate the possibility of utilizing this natural substance as a promising agent in innovative cancer therapy approaches. Melatonin stimulates cell apoptosis via the regulation of many apoptosis facilitators, including mitochondria, cytochrome c, Bcl-2, production of reactive oxygen species, and apoptosis receptors. This paper aimed to further assess the anticancer effects of melatonin through the apoptotic pathway, considering the role that cellular apoptosis plays in the pathogenesis of cancer. The effect of melatonin may mean that it is appropriate for use as an adjuvant, along with other therapeutic approaches such as radiotherapy and chemotherapy.Copyright © 2023 Mafi, Rismanchi, Gholinezhad, Mohammadi, Mousavi, Hosseini, Milasi, Reiter, Ghezelbash, Rezaee, Sheida, Zarepour, Asemi, Mansournia and Mirzaei.